Elastic (ESTC) Q4 Earnings and Revenues Surpass Estimates
Elastic (ESTC) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 27.03%. A quarter ago, it was expected that this software developer would post earnings of $0.47 per share when it actually produced earnings of $0.63, delivering a surprise of 34.04%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Elastic , which belongs to the Zacks Internet - Software industry, posted revenues of $388.43 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 2.20%. This compares to year-ago revenues of $335 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Elastic shares have lost about 6.8% since the beginning of the year versus the S&P 500's gain of 0.1%.
While Elastic has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Elastic: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.43 on $393.05 million in revenues for the coming quarter and $2.11 on $1.67 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Paychex (PAYX), another stock in the same industry, has yet to report results for the quarter ended May 2025.
This payroll processor and human-resources services provider is expected to post quarterly earnings of $1.20 per share in its upcoming report, which represents a year-over-year change of +7.1%. The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level.
Paychex's revenues are expected to be $1.38 billion, up 6.7% from the year-ago quarter.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Elastic N.V. (ESTC) : Free Stock Analysis Report
Paychex, Inc. (PAYX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
8 minutes ago
- CNBC
The biggest risk to valuations is what happens to 10-year rates, says Barclays' Venu Krishna
Venu Krishna, Barclays head of U.S. Equity Strategy, joins 'The Exchange' to discuss Barclays lifting it S&P target to 6,050.
CNBC
9 minutes ago
- CNBC
Health care stocks are due for a turnaround after a historically bad month, according to the charts
The Health Care Select Sector SPDR Fund (XLV) was down over 5% in May, as the S & P 500 gained over 6%, which means that XLV underperformed the index by 11%. That's a huge performance discrepancy. In fact, it was the worst relative monthly percent move vs. the SPX in XLV's history, dating back to late 1998. As is clear from this long-term chart, the odds of this horribly bad relative weakness continuing at this same pace is low – at least for June. XLV itself now has approached two major long-term support levels after the recent downturn. The first is the rising trendline that begins at the 2009 financial crisis low and extends through the Covid bottom. XLV tested this line in mid-May, bounced and finished the month modestly off its lows. The second key support zone comes from the cluster of lows in 2021, 2022 and 2023, noted by the horizontal line that's in the low 120s. The converging lines present a confluence of support that clearly could help XLV's bouncing prospects in June. XLV: The 3 biggest holdings Believe it or not, 34 of XLV's 61 components actually logged gains in May. That's encouraging, but we'll need to see its biggest holdings respond soon. If they can't rally, XLV will continue to struggle. The three largest stocks within the ETF are Eli Lilly , Johnson & Johnson and AbbVie , which make up nearly 27% of XLV combined. So, what are the odds that all three stocks actually can mount strong up-moves in June? Let's take a closer look. We'll start with LLY since it's XLV's biggest component, with a 12% weighting. LLY last made an all-time high in August 2024. From that peak to its April low, the stock lost 30%. But as the following weekly chart (in log scale) shows, it wasn't straight down from there. LLY logged various rallies and drawdowns since then, all of which have taken place within the pictured downward sloping trading channel. The best time to buy LLY, thus, has been after a big, long decline. The stock just fell another 20% from April 30 through May 25. As we can see, the past ensuing bounces yielded big percentage moves, even if they ultimately failed to break through the channel's upper threshold. Additionally, LLY's weekly Williams %R indicator (on the lower panel) is emerging from an oversold condition, which has supported three of the last four big up-moves. In fact, LLY quietly has logged gains in six of the last seven trading days. That's a good start. JNJ (7.7% weight) has been trending lower since topping in 2022, while ABBV (6.8%) has been in a clear uptrend the last few years. However, both have experienced various swings within their respective long-term trading channels — like LLY. And with both JNJ and ABBV having sold off from their 2025 highs, now would be an opportune time for the next bounce to commence. From a big picture market perspective, rotation is an important component of true, long-lasting uptrends. Thus, if/when the air comes out of the more extended sectors and groups soon, capital could find its way to the underperforming areas, which of course, includes health care. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Yahoo
38 minutes ago
- Yahoo
Why Sociedad Quimica y Minera Stock Popped Today
Europe has put lithium on a list of critical metals deserving government subsidies. Chile's SQM primarily mines lithium. Demand for the metal, useful for making electric car batteries, looks set to rise. 10 stocks we like better than Sociedad Química Y Minera De Chile › Shares of Chilean lithium mining company Sociedad Quimica y Minera (NYSE: SQM) -- simply "SQM" to its friends -- jumped 4.9% through 12:10 p.m. ET this afternoon on positive news out of Europe. As Euro News reports, the European Union has prepared a list of 34 raw materials critical to its member countries' economies and deserving of government support. Lithium is on this list, alongside metals such as cobalt and magnesium and various rare earth elements -- all essential components of electric car batteries and electric motors. A 2024 law calls upon the E.U. to locally mine 10% of its annual needs for each of these critical metals, process 40%, and recycle 25%, all by 2030. That doesn't sound like great news for SQM, which of course mines its lithium in Chile for export abroad (including to the E.U.). But as Euro News points out, it's far from certain that Europe will be able to hit its target by the deadline, especially as regards the mining component. Processing and recycling might prove easier, especially if Europe is able to get its lithium mined abroad -- in Chile, for example. And so today's news actually might be a good catalyst for SQM, indicating growing demand in Europe for its primary product. That doesn't necessarily mean you should rush out and buy SQM stock, however. Valued at $8.8 billion in market capitalization, SQM is a profitable company, having earned more than $600 million over the past year. That works out to a seemingly attractive 15 P/E ratio. Free cash flow at the company, however, is much weaker than reported earnings -- only $364 million, resulting in a more expensive price-to-free cash flow ratio of 24. Before you buy stock in Sociedad Química Y Minera De Chile, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Sociedad Química Y Minera De Chile wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Sociedad Quimica y Minera Stock Popped Today was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
